期刊文献+

LRIG1抑制人脑胶质瘤细胞增殖的研究 被引量:3

Effect of LRIG1 on cell proliferation of glioma cell line U251
下载PDF
导出
摘要 目的探讨多亮氨酸重复区免疫球蛋白样蛋白1(LRIG1)对人脑胶质瘤细胞增殖的影响。方法分别构建携带LRIG1、LRIG1小干扰RNA、Bcl2和胶质细胞源性生长因子(BDMF)的质粒,将它们分别转染到人脑胶质瘤细胞系U251细胞内,应用细胞计数试剂盒8法检测细胞活性的变化,蛋白印迹法检测LRIG1、Bcl2、拓扑异构酶Ⅱ(topoⅡ)、GDNF的表达变化。结果成功构建携带LRIG1、LRIG1小干扰RNA、Bcl2、GDNF的质粒,并成功转入U251细胞株。过表达LRIG1显著抑制U251细胞增殖。蛋白印迹法结果显示LRIG1的表达和Bcl2、topoⅡ和GDNF的表达呈显著负相关。结论LRIG1通过负性调节Bcl2、topoⅡ和GDNF的表达抑制人脑胶质瘤细胞系U251细胞的增殖。 ObjectiveTo investigate the effect of leucine-rich repeats and immunoglobulin-like domains protein 1(LRIG1)on cell proliferation of glioma cell line U251.MethodsThe plasmids with LRIG1,LRIG1 siRNA,Bcl-2 or glial cell line-derived neurotrophic factor(GDNF)were constructed and then transfected into the U251 cells,respectively.The cell activities were detected by cell counting kit-8(CCK-8)assay.The expressions of Bcl-2,topoisomeraseⅡ(topoⅡ),GDNF and LRIG1 were detected by western blotting.ResultsThe plasmids with LRIG1,LRIG1 siRNA,Bcl-2 or GDNF were successfully constructed and transfected into U251cells.The cell activities significantly decreased in LRIG1-transfected U251 cells compared with those without(P〈0.05).The expressions of Bcl-2,topoⅡand GDNF significantly decreased in LRIG1-transfected U251 cells compared with those without(P〈0.05),but the expressions of Bcl-2,topoⅡand GDNF significantly increased in LRIG1 siRNA-transfected U251 cells compared with those without(P〈0.05).The expression of LRIG1 significantly decreased in Bcl-2-or GDNF-transfected U251 cells compared with those without(P〈0.05).ConclusionsThe LRIGl can significantly inhibit cell proliferation of glioma cell line U251 cells.It may be by negatively regulating expressions of Bcl-2,topoⅡand GDNF.
出处 《中国临床神经外科杂志》 2013年第10期606-609,共4页 Chinese Journal of Clinical Neurosurgery
基金 国家自然基金资助项目(30973072)
关键词 胶质瘤 U251细胞 多亮氨酸重复区免疫球蛋白样蛋白1 细胞增殖 Glioma cell line U251 cell Proliferation Leucine-rich repeats and immunoglobulin-like domains protein 1
  • 相关文献

参考文献12

  • 1Sathomsumetee S, Rich JN.New treatment strategies formalignant gliomas[J].Expert Rev Anticancer Ther,2006,6:1087-1104.
  • 2Sathomsumetee S, Reardon DA, Desjardins A, et al.Mole-cularly targeted therapy for malignant glioma[J].Cancer,2007, 110:13-24.
  • 3Yi W, Fei Y, Guo DS, et al.Roles and significance of LRIG1gene in human astrocytomas[J].Chinese German J ClinOncol, 2005, 4:225-228.
  • 4纪振刚,刘宝辉,冀保卫,郭振涛,吴立权,田道锋,陈谦学.LRIG1与MnSOD、bcl-2在人脑星形胶质细胞瘤组织芯片中的表达[J].中华实验外科杂志,2011,28(3):476-476. 被引量:3
  • 5Yi W, Haapasalo H, Holmlund C, et al.Expression ofleucine-rich repeats and immunoglobulin-like domains(LRIG) proteins in human ependymoma relates to tumorlocation, WHO grade, and patient age[J].Clin Neuropathol,2009, 28:21-27.
  • 6Ledda F, Bieraugel 0,Fard SS, et al.Lrigl is an endogenousinhibitor of Ret receptor tyrosine kinase activation, downs-tream signaling, and biological responses to GDNF[J].JNeurosci, 2008, 28; 39-49.
  • 7陈谦学,张化明,杨海,吴立权,王军民,邹志鹏,张华.白细胞介素6、信号传导和转录活化因子3和血管内皮生长因子在人脑胶质瘤中的表达及相关性研究[J].中华实验外科杂志,2006,23(12):1457-1459. 被引量:16
  • 8陈谦学,黄乔春,邵步云,叶应湖,王军民.脑胶质瘤增殖活性与转化生长因子-β1的关系[J].中华实验外科杂志,2005,22(9):1109-1110. 被引量:2
  • 9Omuro AM, Faivre S, Raymond E.Lessons learned in thedevelopment of targeted therapy for malignant gliomas[J].Mol Cancer Ther, 2007, 6(7):1909-1919.
  • 10Madhusudan S,Ganesan TS.Tyrosine kinase inhibitors andcancer therapy[J].Recent Results Cancer Res, 2007,172:25-44.

二级参考文献20

  • 1叶飞,郭东升,易伟,牛洪泉,舒凯,万锋,卢运萍,雷霆.过度表达LRIG1基因逆转人胶质瘤侵袭性的机制[J].中华实验外科杂志,2005,22(2):200-202. 被引量:26
  • 2沈剑峰,曹浩强,周永庆,詹仁雅,黄琼,徐庆生,马廉亭.脑胶质瘤中环氧化酶-2和血管内皮生长因子的表达及作用[J].中华实验外科杂志,2005,22(3):338-340. 被引量:6
  • 3Naoshi Y, Mitsuyasu K, Hidetoshi Y, et al, Enhanced expression of TGF-β3 and its type-1 and type-2 receptors in human glioblastoma, Int J Cancer, 1995, 62: 386-392.
  • 4Samuels V, Barrett JM, Bockman S, et al, Immunocytochemical study of transforming growth factor expression in benign and malignant glioma.Am J Pathol, 1989, 134:894-902.
  • 5Dunn IF, Heese O, Black PM, et al. Growth factors in glioma angiogenesis FGFs, PDGF, EGF, and TGFs. J Neurooncol, 2000, 50:121-137.
  • 6Naganuma H, Sasaki A, Satoh E, et al, Down-regulation of transforming growth factor β and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs,J Neurooncol, 1998, 39:227-236.
  • 7Bromberg J. Stat proteins and oncogenesis. J Clin Invest, 2002, 109 :1139-1142.
  • 8Niu G, Wright KL, Huang M, et al. Constitutive STAT3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene, 2002,21: 2000-2008.
  • 9Bromberg J, Damell J E. The role of stats in transcriptional control and their impact on cellular function. Oncogene,2000,19:2468-2473.
  • 10Leong PL, Andrews GA, Johnson DE, et al. Target-inhibition of STAT3 with a decoy oligonucleotideabrogates head and neck cancer cell growth. Proc Natl Acad Sci USA,2003,100:4138-4143.

共引文献25

同被引文献26

  • 1Nilsson J, Vallbo C, Guo D, et al. Cloning, characterization, and expression of human LIG1 [J]. Biochem Biophys Res Commun, 2001, 284(5): 1155-1161.
  • 2Liu B, Guo Z, Dong H, et al. LRIG1, human EGFR inhibitor, reverses muhidrug resistance through modulation of ABCB 1 and ABCG2 [J]. Brain Res, 2015, 1611: 93-100.
  • 3Yi W, Holmlund C, Nilsson J, et al. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1 [J]. Exp Cell Res, 2010, 317(4): 504-512.
  • 4丁昊,周志伟,易伟,等.LRIGl相关功能片段对EGFR活性和胶质瘤细胞增殖的影响[J].中国临床神经外科杂志,2013,18:606-609.
  • 5Goldoni S, Iozzo RA, Kay P, et al. A soluble ectodomain of LRIG1 inhibits cancer growth by attenuating basal and ligand-dependent EGFR activity [J]. Oncogene, 2007, 26 (3): 368-381.
  • 6Mao F, Wang B, Xiao Q, et al. A role for LRIG1 in the regu- lation of malignant glioma aggressiveness [J]. Int J Oncol, 2013, 42(3): 1081-1087.
  • 7Stutz MA, Shattuck DL, Laederich MB, et al. LRIG1 nega- tively regulates the oncogenic EGF receptor mutant EGFRvIII [J]. Oncogene, 2008, 27(43): 5741-5752.
  • 8Yang HW, Menon LG, Black PM, et al. SNAI2/Slug pro- motes growth and invasion in human gliomas [J]. BMC Cancer, 2010, 10: 301.
  • 9Barami K, Lewis-Tuffin L, Anastasiadis PZ. The role of cadherins and catenins in gliomagenesis [J]. Neurosurg Focus, 2006, 21(4): E13.
  • 10Yu H, Shen Y, Hong J, et al. The contribution of TGF-β in Epithelial-Mesenchymal Transition (EMT): Down-regula- tion of E-cadherin via snail [J]. Neoplasma, 2015, 62(1): 1- 15.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部